HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function

Oncogene

Volumn 27, Issue 7, 2008, Pages 997-1003

  Lau, L M S ^a,b   Nugent, J K ^b   Zhao, X ^a   Irwin, M S ^a,b,c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Apoptosis; HDM2; Nutlin; p53; p73

Indexed keywords

NUTLIN 3; PROTEIN MDM2; PROTEIN NOXA; PROTEIN P21; PROTEIN P73; PUMA PROTEIN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; BINDING AFFINITY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN INTERACTION; TRANSCRIPTION INITIATION; UPREGULATION;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BONE NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA-BINDING PROTEINS; HCT116 CELLS; HUMANS; IMIDAZOLES; IMMUNOBLOTTING; IMMUNOPRECIPITATION; NUCLEAR PROTEINS; OSTEOSARCOMA; PIPERAZINES; PROTEIN BINDING; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 38949199337     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210707     Document Type: Article

References (30)

1. Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK. (2007). Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene 26: 3473-3481.
2. Balint E, Bates S, Vousden KH. (1999). Mdm2 binds p73 alpha without targeting degradation. Oncogene 18: 3923-3929.
3. Bergamaschi D, Samuels Y, Jin B, Duraisingham S, Crook T, Lu X. (2004). ASPP1 and ASPP2: common activators of p53 family members. Mol Cell Biol 24: 1341-1350.
4. Bottger V, Bottger A, Garcia-Echeverria C, Ramos YF, van der Eb AJ, Jochemsen AG et al. (1999). Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene 18: 189-199.
5. Calabro V, Mansueto G, Parisi T, Vivo M, Calogero RA, LaMantia G. (2002). The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63. J Biol Chem 277: 2674-2681.
6. Coll-Mulet L, Iglesias-Serret D, Santidrian AF, Cosialls AM, de Frias M, Castano E et al. (2006). MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 107: 4109-4114.
7. Hibi K, Trink B, Patturajan M, Westra WH, Caballero OL, Hill DE et al. (2000). AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA 97: 5462-5467.
8. Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W et al. (2000). Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 407: 645-648.
9. Irwin MS. (2004). Family feud in chemosensitivity: p73 and mutant p53. Cell Cycle 3: 319-323.
10. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin Jr WG. (2003). Chemosensitivity linked to p73 function. Cancer Cell 3: 403-410.
11. Iwakuma T, Lozano G. (2003). MDM2, an introduction. Mol Cancer Res 1: 993-1000.
12. Kadakia M, Slader C, Berberich SJ. (2001). Regulation of p63 function by Mdm2 and MdmX. DNA Cell Biol 20: 321-330.
13. Kulikov R, Winter M, Blattner C. (2006). Binding of p53 to the central domain of Mdm2 is regulated by phosphorylation. J Biol Chem 281: 28575-28583.
14. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ et al. (1996). Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948-953.
15. Larusch GA, Jackson MW, Dunbar JD, Warren RS, Donner DB, Mayo LD. (2007). Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction b. Cancer Res 67: 450-454.
16. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C et al. (2006). Inactivation of the p53 pathway in retinoblastoma. Nature 444: 61-66.
17. Ma J, Martin JD, Zhang H, Auger KR, Ho TF, Kirkpatrick RB et al. (2006). A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination. Biochemistry 45: 9238-9245.
18. Ongkeko WM, Wang XQ, Siu WY, Lau AW, Yamashita K, Harris AL et al. (1999). MDM2 and MDMX bind and stabilize the p53-related protein p73. Curr Biol 9: 829-832.
19. Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW. (2006). Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res 66: 3169-3176.
20. Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW. (2006). p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 9: 45-56.
21. Shimizu H, Burch LR, Smith AJ, Dornan D, Wallace M, Ball KL et al. (2002). The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo. J Biol Chem 277: 28446-28458.
22. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H et al. (2006). Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 103: 1888-1893.
23. Van Maerken T, Speleman F, Vermeulen J, Lambertz I, De Clercq S, De Smet E et al. (2006). Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res 66: 9646-9655.
24. VanderBorght A, Valckx A, Van Dun J, Grand-Perret T, De Schepper S, Vialard J et al. (2006). Effect of an hdm-2 antagonist peptide inhibitor on cell cycle progression in p53-deficient H1299 human lung carcinoma cells. Oncogene 25: 6672-6677.
25. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848.
26. Wallace M, Worrall E, Pettersson S, Hupp TR, Ball KL. (2006). Dualsite regulation of MDM2 E3-ubiquitin ligase activity. Mol Cell 23: 251-263.
27. Wang X, Arooz T, Siu WY, Chiu CH, Lau A, Yamashita K et al. (2001). MDM2 and MDMX can interact differently with ARF and members of the p53 family. FEBS Lett 490: 202-208.
28. Watson IR, Blanch A, Lin DC, Ohh M, Irwin MS. (2006). Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function. J Biol Chem 281: 34096-34103.
29. Zeng X, Chen L, Jost CA, Maya R, Keller D, Wang X et al. (1999). MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol 19: 3257-3266.
30. Zhang Z, Wang H, Li M, Agrawal S, Chen X, Zhang R. (2004). MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J Biol Chem 279: 16000-16006.